APA (7th ed.) Citation

SH, L., HY, L., V, V., M, X., PF, T., L, Y., . . . GR, B. (2022). Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer treatment and research communications, 30, 100514. https://doi.org/10.1016/j.ctarc.2022.100514

Chicago Style (17th ed.) Citation

SH, Lin, et al. "Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer." Cancer Treatment and Research Communications 30 (2022): 100514. https://doi.org/10.1016/j.ctarc.2022.100514.

MLA (9th ed.) Citation

SH, Lin, et al. "Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer." Cancer Treatment and Research Communications, vol. 30, 2022, p. 100514, https://doi.org/10.1016/j.ctarc.2022.100514.